Trastuzumab PHERGain Trial: Unveiling 3-Year iDFS in HER2+ Early Breast Cancer Breast 2 Mins Read2 Dr. Javier Cortes discussed the PHERGain clinical study is a phase 2 trial focused on the potential deescalation of chemotherapy…
